Agent for treating fabry disease, analgesic for external use and perspiration accelerator
Patent Information
- Authority / Receiving Office
- CN Β· China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- OSAKA UNIV
- Publication Date
- 2018-10-23
- Estimated Expiration
- Not applicable Β· inactive patent
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to a therapeutic agent for Fabry's disease, an analgesic for external use and a sweating enhancer. Background technique
[0002] Fabry disease is a genetic disorder resulting from the congenital absence of a lysosomal enzyme, Ξ±-galactosidase (Ξ±-Gal), resulting in its substrate, trihexosylceramide (GL-3) or galactosidase Lactosebiosylceramide (GL-2), blood type B glycolipids and other glycolipids with galactose at the non-reducing end are stored in lysosomes, and then stored in vascular endothelial cells, cardiomyocytes, ganglion All kinds of cells headed by cells, thus showing various clinical symptoms related to the organs of the whole body.
[0003] Various symptoms such as cardiac dysfunction, renal dysfunction, neurological symptoms accompanied by pain, angiokeratoma, and corneal opacity occur due to organ damage due to accumulation of GL-3 and the like.
[0004] Therefore, symptoms of Fabry's disease, which is considered to...